{"id":47989,"date":"2025-11-14T14:33:27","date_gmt":"2025-11-14T06:33:27","guid":{"rendered":"https:\/\/flcube.com\/?p=47989"},"modified":"2025-12-30T21:03:20","modified_gmt":"2025-12-30T13:03:20","slug":"jiangsu-hengruis-rezvilutamide-clears-nmpa-hurdle-moves-into-phase-iii-prostate-cancer-trial","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=47989","title":{"rendered":"Jiangsu Hengrui\u2019s Rezvilutamide Clears NMPA Hurdle, Moves Into Phase\u202fIII Prostate\u2011Cancer Trial"},"content":{"rendered":"\n<p><strong>Jiangsu Hengrui Pharmaceuticals Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1276:HKG\">HKG:\u202f1276<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/600276:SHA\">SHA: 600276<\/a>) announced today that its second\u2011generation androgen\u2011receptor inhibitor <strong>rezvilutamide<\/strong> has received <strong>National Medical Products Administration (NMPA)<\/strong> approval to commence a <strong>Phase\u202fIII pivotal study<\/strong> in patients with <strong>prostate cancer<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile\">Drug Profile<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Name<\/strong><\/td><td>Rezvilutamide (tablet)<\/td><\/tr><tr><td><strong>Class<\/strong><\/td><td>Second\u2011generation androgen\u2011receptor (AR) inhibitor<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Potent AR antagonism with <strong>no agonist activity<\/strong>; higher binding affinity than first\u2011generation AR blockers<\/td><\/tr><tr><td><strong>Current indication (2022)<\/strong><\/td><td>High\u2011volume metastatic hormone\u2011sensitive prostate cancer (mHSPC) \u2013 already marketed in China<\/td><\/tr><tr><td><strong>Phase\u202fIII indication<\/strong><\/td><td>Treatment\u2011na\u00efve or progressive <strong>prostate cancer<\/strong> (including castration\u2011resistant disease)<\/td><\/tr><tr><td><strong>Comparator drugs<\/strong><\/td><td>Enzalutamide, Apalutamide, Darolutamide (both domestic and global markets)<\/td><\/tr><tr><td><strong>Trial design<\/strong><\/td><td>Randomized, double\u2011blind, 1,200\u2011patient global enrollment; primary endpoint \u2013 overall survival (OS)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Domestic AR\u2011inhibitor landscape:<\/strong> China hosts several approved second\u2011generation AR blockers, yet <strong>rezvilutamide<\/strong> differentiates itself with a <strong>stronger AR blockade<\/strong> and a <strong>cleaner safety profile<\/strong> (no partial agonism).<\/li>\n\n\n\n<li><strong>Global competition:<\/strong> Enzalutamide, Apalutamide, and Darolutamide dominate the worldwide market, together accounting for <strong>\u2248\u202fUS$5\u202fbn<\/strong> in annual sales. Hengrui aims to capture a share of the <strong>fast\u2011growing Chinese prostate\u2011cancer market<\/strong>, projected to reach <strong>CNY\u202f30\u202fbn<\/strong> by 2030.<\/li>\n\n\n\n<li><strong>Revenue outlook:<\/strong> Assuming a <strong>10\u202f% market share<\/strong> of the Chinese mCRPC segment post\u2011approval, rezvilutamide could generate <strong>CNY\u202f3\u20134\u202fbn<\/strong> in annual sales within five years.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Portfolio deepening:<\/strong> The Phase\u202fIII clearance expands Hengrui\u2019s oncology pipeline beyond its existing mHSPC label, positioning the company for a <strong>full\u2011line AR\u2011inhibitor franchise<\/strong>.<\/li>\n\n\n\n<li><strong>Regulatory credibility:<\/strong> NMPA approval for a pivotal trial underscores Hengrui\u2019s <strong>robust clinical\u2011development capability<\/strong>, potentially easing future submissions for additional indications.<\/li>\n\n\n\n<li><strong>Potential partnerships:<\/strong> Success in Phase\u202fIII may attract <strong>co\u2011development or licensing deals<\/strong> with multinational pharma firms seeking entry into the Chinese market.<\/li>\n<\/ol>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the Phase\u202fIII trial, market potential, and strategic impact. Actual results may differ due to clinical outcomes, regulatory decisions, competitive dynamics, and other risks disclosed in Hengrui\u2019s most recent annual report and filings.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/600276_20251114_KOS9.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 600276_20251114_KOS9.\"><\/object><a id=\"wp-block-file--media-17f8fab0-b89e-49fd-bb4d-74af9a8dc2ca\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/600276_20251114_KOS9.pdf\">600276_20251114_KOS9<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/600276_20251114_KOS9.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-17f8fab0-b89e-49fd-bb4d-74af9a8dc2ca\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG:\u202f1276, SHA: 600276) announced today that its second\u2011generation androgen\u2011receptor inhibitor&#8230;<\/p>\n","protected":false},"author":1,"featured_media":48072,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,62,2586,4228,852],"class_list":["post-47989","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-clinical-trial-approval-initiation","tag-hengrui-pharmaceuticals","tag-hkg-1276","tag-sha-600276"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Jiangsu Hengrui\u2019s Rezvilutamide Clears NMPA Hurdle, Moves Into Phase\u202fIII Prostate\u2011Cancer Trial - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG:\u202f1276, SHA: 600276) announced today that its second\u2011generation androgen\u2011receptor inhibitor rezvilutamide has received National Medical Products Administration (NMPA) approval to commence a Phase\u202fIII pivotal study in patients with prostate cancer.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=47989\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Jiangsu Hengrui\u2019s Rezvilutamide Clears NMPA Hurdle, Moves Into Phase\u202fIII Prostate\u2011Cancer Trial\" \/>\n<meta property=\"og:description\" content=\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG:\u202f1276, SHA: 600276) announced today that its second\u2011generation androgen\u2011receptor inhibitor rezvilutamide has received National Medical Products Administration (NMPA) approval to commence a Phase\u202fIII pivotal study in patients with prostate cancer.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=47989\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-14T06:33:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-30T13:03:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1302-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47989#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47989\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Jiangsu Hengrui\u2019s Rezvilutamide Clears NMPA Hurdle, Moves Into Phase\u202fIII Prostate\u2011Cancer Trial\",\"datePublished\":\"2025-11-14T06:33:27+00:00\",\"dateModified\":\"2025-12-30T13:03:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47989\"},\"wordCount\":348,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47989#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1302-1.webp\",\"keywords\":[\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"Hengrui Pharmaceuticals\",\"HKG: 1276\",\"SHA: 600276\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=47989#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47989\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=47989\",\"name\":\"Jiangsu Hengrui\u2019s Rezvilutamide Clears NMPA Hurdle, Moves Into Phase\u202fIII Prostate\u2011Cancer Trial - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47989#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47989#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1302-1.webp\",\"datePublished\":\"2025-11-14T06:33:27+00:00\",\"dateModified\":\"2025-12-30T13:03:20+00:00\",\"description\":\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG:\u202f1276, SHA: 600276) announced today that its second\u2011generation androgen\u2011receptor inhibitor rezvilutamide has received National Medical Products Administration (NMPA) approval to commence a Phase\u202fIII pivotal study in patients with prostate cancer.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47989#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=47989\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47989#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1302-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1302-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Jiangsu Hengrui\u2019s Rezvilutamide Clears NMPA Hurdle, Moves Into Phase\u202fIII Prostate\u2011Cancer Trial\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47989#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Jiangsu Hengrui\u2019s Rezvilutamide Clears NMPA Hurdle, Moves Into Phase\u202fIII Prostate\u2011Cancer Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Jiangsu Hengrui\u2019s Rezvilutamide Clears NMPA Hurdle, Moves Into Phase\u202fIII Prostate\u2011Cancer Trial - Insight, China&#039;s Pharmaceutical Industry","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG:\u202f1276, SHA: 600276) announced today that its second\u2011generation androgen\u2011receptor inhibitor rezvilutamide has received National Medical Products Administration (NMPA) approval to commence a Phase\u202fIII pivotal study in patients with prostate cancer.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=47989","og_locale":"en_US","og_type":"article","og_title":"Jiangsu Hengrui\u2019s Rezvilutamide Clears NMPA Hurdle, Moves Into Phase\u202fIII Prostate\u2011Cancer Trial","og_description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG:\u202f1276, SHA: 600276) announced today that its second\u2011generation androgen\u2011receptor inhibitor rezvilutamide has received National Medical Products Administration (NMPA) approval to commence a Phase\u202fIII pivotal study in patients with prostate cancer.","og_url":"https:\/\/flcube.com\/?p=47989","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-14T06:33:27+00:00","article_modified_time":"2025-12-30T13:03:20+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1302-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=47989#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=47989"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Jiangsu Hengrui\u2019s Rezvilutamide Clears NMPA Hurdle, Moves Into Phase\u202fIII Prostate\u2011Cancer Trial","datePublished":"2025-11-14T06:33:27+00:00","dateModified":"2025-12-30T13:03:20+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=47989"},"wordCount":348,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=47989#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1302-1.webp","keywords":["Cancer","Clinical trial approval \/ initiation","Hengrui Pharmaceuticals","HKG: 1276","SHA: 600276"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=47989#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=47989","url":"https:\/\/flcube.com\/?p=47989","name":"Jiangsu Hengrui\u2019s Rezvilutamide Clears NMPA Hurdle, Moves Into Phase\u202fIII Prostate\u2011Cancer Trial - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=47989#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=47989#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1302-1.webp","datePublished":"2025-11-14T06:33:27+00:00","dateModified":"2025-12-30T13:03:20+00:00","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG:\u202f1276, SHA: 600276) announced today that its second\u2011generation androgen\u2011receptor inhibitor rezvilutamide has received National Medical Products Administration (NMPA) approval to commence a Phase\u202fIII pivotal study in patients with prostate cancer.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=47989#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=47989"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=47989#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1302-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1302-1.webp","width":1080,"height":608,"caption":"Jiangsu Hengrui\u2019s Rezvilutamide Clears NMPA Hurdle, Moves Into Phase\u202fIII Prostate\u2011Cancer Trial"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=47989#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Jiangsu Hengrui\u2019s Rezvilutamide Clears NMPA Hurdle, Moves Into Phase\u202fIII Prostate\u2011Cancer Trial"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1302-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/47989","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=47989"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/47989\/revisions"}],"predecessor-version":[{"id":48073,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/47989\/revisions\/48073"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/48072"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=47989"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=47989"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=47989"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}